1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Irritable Bowel Syndrome - Current and Future Players

PharmaPoint: Irritable Bowel Syndrome - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Irritable Bowel Syndrome - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Irritable Bowel Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Irritable Bowel Syndrome market. The report provides insight into the competitive Irritable Bowel Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Irritable Bowel Syndrome
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Irritable Bowel Syndrome sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Irritable Bowel Syndrome market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Irritable Bowel Syndrome market landscape? Identify, understand and capitalize

Table Of Contents

PharmaPoint: Irritable Bowel Syndrome - Current and Future Players
1 Table of Contents
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
3 Market Outlook 13
3.1 Global Markets 13
3.1.1 Forecast 13
3.1.2 Drivers and Barriers - Global Issues 17
4 Current and Future Players 19
4.1 Overview 19
4.2 Trends in Corporate Strategy 21
4.3 Company Profiles 22
4.3.1 Actavis 22
4.3.2 Astellas 24
4.3.3 Almirall 27
4.3.4 Ironwood 28
4.3.5 Takeda 31
4.3.6 Sucampo 33
4.3.7 Prometheus 35
4.3.8 Salix 37
4.3.9 Menarini 39
4.3.10 Synergy 41
4.3.11 AstraZeneca 43
5 Appendix 45
5.1 Bibliography 45
5.2 Abbreviations 46
5.3 Methodology 47
5.4 Forecasting Methodology 47
5.4.1 Diagnosed IBS Patients 47
5.4.2 General Pricing Assumptions 48
5.4.3 Generic Erosion 49
5.5 Primary Research - KOLs Interviewed for This Report 49
5.6 About the Authors 51
5.6.1 Analyst 51
5.6.2 Therapy Area Director 51
5.6.3 Global Head of Healthcare 52
5.7 About GlobalData 53
5.8 Disclaimer 53

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for IBS, 2013-2023 15
Table 2: Global IBS Market - Drivers and Barriers, 2013-2023 17
Table 3: Key Companies in the IBS Market in the 7MM, 2014 20
Table 4: Actavis' IBS Portfolio Assessment, 2014 23
Table 5: Astellas' IBS Portfolio Assessment, 2014 25
Table 6: Almirall's IBS Portfolio Assessment, 2014 27
Table 7: Ironwood's IBS Portfolio Assessment, 2014 29
Table 8: Takeda's IBS Portfolio Assessment, 2014 31
Table 9: Sucampo's IBS Portfolio Assessment, 2014 33
Table 10: Prometheus' IBS Portfolio Assessment, 2014 35
Table 11: Salix's IBS Portfolio Assessment, 2014 37
Table 12: Menarini's IBS Portfolio Assessment, 2014 39
Table 13: Synergy's IBS Portfolio Assessment, 2014 41
Table 14: AstraZeneca's IBS Portfolio Assessment, 2014 43

1.2 List of Figures

Figure 1: Global Sales for IBS by Region, 2013-2023 16
Figure 2: Company Portfolio Gap Analysis in IBS, 2013-2023 21
Figure 3: Actavis' SWOT Analysis in IBS, 2013-2023 24
Figure 4: Astellas' SWOT Analysis in IBS, 2013-2023 26
Figure 5: Almirall's SWOT Analysis in IBS, 2013-2023 28
Figure 6: Ironwood's SWOT Analysis in IBS, 2013-2023 30
Figure 7: Takeda's SWOT Analysis in IBS, 2013-2023 32
Figure 8: Sucampo's SWOT Analysis in IBS, 2013-2023 34
Figure 9: Prometheus' SWOT Analysis in IBS, 2013-2023 36
Figure 10: Salix's SWOT Analysis in IBS, 2013-2023 38
Figure 11: Menarini's SWOT Analysis in IBS, 2013-2023 40
Figure 12: Synergy's SWOT Analysis in IBS, 2013-2023 42
Figure 13: AstraZeneca's SWOT Analysis in IBS, 2013-2023 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.